Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Interventional × FP-1039 × Clear all

Phase

Status

Completed 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Endometrial Neoplasms 1

Interventions

Cyclophosphamide 105 Radiotherapy 102 Cisplatin 102 pembrolizumab 96 Paclitaxel 83 Carboplatin 82 Gemcitabine 76 Nivolumab 69 Magnetic Resonance Spectroscopy 66 Fluorouracil 64 Dexamethasone 60 Bevacizumab 59 Radiosurgery 56 Docetaxel 56 Rituximab 50 Oxaliplatin 48 Leucovorin 48 Capecitabine 47 fludarabine 45 Doxorubicin 42 Biopsy 42 durvalumab 40 Pemetrexed 37 Drug Therapy 37 fludarabine phosphate 36 Etoposide 36 Cytarabine 35 Radiation 33 Lenalidomide 32 Melphalan 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01244438 2021-12-13

Study of FP-1039 in Subjects With Endometrial Cancers

Five Prime Therapeutics, Inc.

Phase 2 Withdrawn

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡